Prognostic value of pretreatment contrast-enhanced computed tomography in esophageal neuroendocrine carcinoma: A multi-center follow-up study

Table 1 Basic clinical factors and computed tomography characteristics of the patients

Variable	Statistics, n (%)
Gender
Male	53 (69)
Female	24 (31)
Median age (yr)1	64 (42-78)
Morphological subtype
Medullary type	34 (44)
Mushroom type	31 (40)
Ulcer type	12 (16)
Narrowing type	18 (23)
Tumor length (mm)1	39.9 (10-118.9)
Tumor location
Upper segment esophagus	5 (6)
Middle segment esophagus	45 (58)
Lower segment esophagus	27 (35)
Clinical symptom
Progressive dysphagia	48 (62)
Abdominal/retrosternal pain	15 (20)
Loss of appetite	12 (15)
Fever	2 (3)
Immunohistochemical result
CK	57 (74)
CgA	25 (32)
Syn	63 (82)
NSE	22 (29)
Ki-67 (%)1	80 (40-95)
Thickness of esophageal tumor wall (mm)1	11 (2-27.93)
Treatment strategy
Esophagectomy only	9 (12)
Chemotherapy	1 (1)
Chemo radiotherapy	1 (1)
Postoperative adjuvant chemoradiotherapy	67 (87)
Progression-free survival (mo)1	6.2 (0.3-45)
Overall survival (mo)1	12.6 (0.9-64.8)

Except where indicated, data are numbers of patients, with percentages in parentheses.

¹Data are medium values, and numbers in parentheses are ranges. CK: Cytokeratin; CgA: Chromogranin A; Syn: Synaptophysin; NSE: Neuron-specific enolase.